Click here for a complete list of CME opportunities.
The American Academy of HIV Medicine www.aahivm.org
Bibliography
Displaying 76 - 90 of 1762
Arribas JR, Pialoux G, Gathe J, et al. Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase IIIb, non-inferiority trial. Lancet Infect Dis. 2014;14:581-589.
Arribas JR, Thompson M, Sax PE, et al. Significant efficacy and long-term safety difference with TAF-based STR in naïve adults. Program and abstracts of the 2017 Conference on Retroviruses and Opportunistic Infections; February 13-16, 2017; Seattle, Washington. Abstract 453.
Arthos J, Cicala C, Martinelli E, et al. HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol. 2008;9:301-309.
American Society of Health Systems Pharmacists. (2015). ASHP Guidelines on Pharmacist Involvement in HIV Care. In: ASHP best practices. Position & Guidance Documents of ASHP 2015-2016 edition. Bethesda: American Society of Health Systems Pharmacists.
Antiretroviral Therapy Cohort C. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010; 50(10):1387-1396.
Atkinson MJ, Petrozzino JJ. An evidence-based review of treatment-related determinants of patients’ nonadherence to HIV medications. AIDS Patient Care STDS 11 (2009):903–14.
Atta MG, Gallant JE, Rahman MH, et al. Antiretroviral therapy in the treatment of HIV-associated nephropathy. Nephrol Dial Transplant 10 (2006):2809.
Atta MG, Lucas G, Fine DM. HIV-associated nephropathy: Epidemiology, pathogenesis, diagnosis and management. Expert Rev Anti Infect Ther. 2008;6:365-371.
Aukrust P, Haug CJ, Ueland T, et al. Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab 84.1 (1999):145.
Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, et al. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: The ANRS 1265 trial. PLoS Med. 2005;2:e298.
AVAC. Preexposure Prophylaxis (PrEP) by the numbers. Available at: http://www.avac.org/sites/default/files/resource-files/prep_BTN_aug2016.pdf. Accessed April 12, 2017.
AVAC. Regulatory status of TDF-FTC for PrEP. Available at http://www.avac.org/infographic/regulatory-status-tdfftc-prep. Accessed April 11, 2017.
Bachmeyer C, Blanche P, Sereni D, et al. Thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome in HIV-infected patients. AIDS. 1995;9:532-533.
Baeten JM. Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399-410.
Baeten JM, Palanee-Phillips T, Brown ER, et al. Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women. N Engl J Med. 2016; 375:2121-2132.
Pages
Featured Resources
Pair up with one of the Academy's experienced and credentialed providers for one-on-one guidance. No matter where you are on your journey, an Academy Mentor can help you reach your personal goals.
Contact
AAHIVM National Office
1627 Eye St NW Suite 835
Washington, D.C. 20006
About
The American Academy of HIV Medicine is a professional organization that supports the HIV practitioner and promotes accessible, quality care for all Americans living with HIV disease. Our membership of HIV practitioners and credentialed HIV Specialists™, HIV Experts™, and HIV Pharmacists™ provide direct care to the majority of HIV patients in the US.